Sorrento Therapeutics Inc (SRNE): Compare Sorrento's results to AZ&#39...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5700
Boards Moderated	0
Alias Born	12/13/2004

dia76ca

Re: None

Wednesday, 10/27/2021 8:25:41 PM

Wednesday, October 27, 2021 8:25:41 PM

Compare Sorrento's results to AZ's Nov.12, 2020...
AZ’s BTK inhibitor Calquence fails in COVID-19 study
Therapy is already approved to treat a number of blood cancers

"AstraZenea’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence has failed to improve survival and prevent respiratory failure in hospitalised COVID-19 patients.

The CALAVI phase 2 trials had been evaluating the efficacy and safety of Calquence (acalabrutinib) alongside best supportive care (BCS) in patients hospitalised with respiratory complications of COVID-19.

The primary endpoint, measuring respiratory failure or death, was not met, with the addition of Calquence to BCS failing to increase the number of patients who remained alive and free of respiratory failure compared to placebo.""

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent SRNE News

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM